CAR-T cells for leukaemia therapy - HD stock video

Scanning electron microscopy of genetically-engineered CAR-T cells used to treat lymphoblastic leukaemia, a type of blood cancer. Chimeric antigen receptor T cells (CAR-T) are the basis of a new therapy that uses T-lymphocyte white blood cells from the patient's blood, which are removed from the body and genetically engineered to produce a receptor to an antigen on the patient's cancerous cells. The newly modified CAR-T cells are returned to the body, where they selectively attack and destroy the cancer cells. The therapy was approved by FDA in the USA in August 2017. The Clinical Cell and Vaccine Production Facility the University of Pennsylvania under Dr. Bruce Levine developed the therapy, called Kymriah (Tisagenlecleucel), for NOVARTIS. The cells are seen attached to microbeads which bear the antibodies that bind to the antigens on the T cells. This activates the T cells, inducing cell division and growth. The field of view at the start of the clip is around 48x27 micrometres, one the smallest 360 SEM movies made to date